Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

The 40mg-Copaxone patent case in US District Court (scheduled for 9/26/16) is separate from the IPR at the US PTO. Only the Court can issue an injunction against NVS/MNTA’s launch, so it’s the Court’s ruling that matters vis-à-vis an at-risk launch.

In #msg-124628031, I pointed out this distinction in the first sentence.